secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-020826
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen Q1 2023 net loss $16.3M; cash $165.4M; pipeline milestones on track
--------------------------------------------------------------------------

- Net loss of $16.3M for Q1 2023 vs $18.2M in Q1 2022; R&D expense $14.4M, G&A $3.7M.
- Cash, cash equivalents, and investments of $165.4M as of March 31, 2023; runway into early 2025.
- Phase 2 CONNECT1-EDO51 (open-label) for DMD expected to start in Canada H1 2023.
- Phase 2 CONNECT2-EDO51 (randomized, placebo-controlled) multinational study expected H2 2023.
- Phase 1 FREEDOM-DM1 for myotonic dystrophy type 1 expected to start H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017023020826/0000950170-23-020826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017023020826/pepg-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer